PRESCRIBING INFORMATION

Lanreotide Ipsen solution for injection in a pre-filled syringe

See full Summary of Product Characteristics (SmPC) before prescribing. Available at www.medicines.org.uk  

Presentation: Pre-filled syringe containing a solution of lanreotide (as acetate) 60, 90 or 120mg per syringe. Indications: (1) Treatment of acromegaly when circulating levels of growth hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. (2) Treatment of Grade 1 and a subset of Grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin (where hindgut sites have been excluded) in adults with unresectable locally advanced or metastatic disease. (3) Treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours. Dosage: Acromegaly: Starting dose 60 to 120mg administered via deep subcutaneous injection every 28 days. Dose individualised according to patient’s response (judged by reduction in symptoms and/or reduction in GH and/or IGF-1 levels) up to a maximum of 120mg every 28 days. Patients well controlled on a somatostatin analogue can alternatively be treated with Lanreotide Ipsen 120 mg every 42-56 days (6 to 8 weeks). GEP-NETs Treatment: One deep subcutaneous injection of 120mg every 28 days for as long as needed for tumour control. NET Symptoms: Starting dose 60 to 120mg administered via deep subcutaneous injection every 28 days. The dose should be adjusted according to degree of symptomatic relief obtained. Elderly, renal and/or hepatic impairment:  No dose modification necessary due to the wide therapeutic window. Paediatric population: The safety and efficacy in children and adolescents has not been established.  Method of administration: Lanreotide Ipsen should be injected via the deep subcutaneous route into the superior external quadrant of the buttock or in the upper outer thigh. For patients who receive a stable dose, and after appropriate training, the injection may be given by the patient themselves or another trained person. In the case of self-injection, the injection should be given in the upper outer thigh. A healthcare professional should decide who should administer the injections. Regardless of the injection site, the skin should not be folded, and the needle should be inserted rapidly and to its full length, perpendicularly to the skin. The injection site should alternate between the right and left side. Contraindications: Hypersensitivity to lanreotide, somatostatin or related peptides or any of the excipients. Precautions and warnings: Lanreotide Ipsen may reduce gallbladder motility and lead to gallstone formation. Patients may require periodic monitoring. There have been post-marketing reports of gallstones resulting in complications, including cholecystitis, cholangitis, and pancreatitis, requiring cholecystectomy in patients taking lanreotide. If complications of cholelithiasis are suspected, discontinue Lanreotide Ipsen and treat appropriately. Patients treated with Lanreotide Ipsen may experience hypoglycaemia or hyperglycaemia. Blood glucose levels should be monitored at the start of treatment or when the dose is altered, and any anti-diabetic requirements should be adjusted accordingly. Slight decreases in thyroid function have been observed in patients with acromegaly. Thyroid function tests are recommended where clinically indicated. Lanreotide Ipsen may lead to a decrease of heart rate in patients without underlying cardiac problems, and sinus bradycardia in those with cardiac disorders. Care should be taken when initiating treatment in patients with bradycardia. Interactions: The pharmacological gastrointestinal effects of lanreotide may result in a reduction of the intestinal absorption of co-administered drugs including ciclosporin. Concomitant administration of ciclosporin may decrease the relative bioavailability of ciclosporin and therefore may necessitate the adjustment of ciclosporin dose to maintain therapeutic levels. Concomitant administration of bromocriptine may increase the bioavailability of bromocriptine. Concomitant administration of bradycardia inducing drugs (e.g. beta blockers) may have an additive effect on the slight reduction of heart rate associated with lanreotide. Dose adjustments of such concomitant medications may be necessary. The limited published data available indicate that somatostatin analogues may decrease clearance of drugs metabolised via CYP450 enzymes.  Drugs with a low therapeutic index mainly metabolised via CYP3A4 (e.g. quinidine, terfenadine) should be used with caution. Pregnancy and lactation: There are a limited amount of data (less than 300 pregnancy outcomes) from the use of lanreotide in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. As a precautionary measure, it is preferable to avoid the use of Lanreotide Ipsen during pregnancy. Lanreotide Ipsen should not be used during breast-feeding as it is not known whether it is excreted in human milk. Undesirable effects: Very common: diarrhoea, loose stools, abdominal pain, cholelithiasis. Common: ALAT increased, ASAT abnormal, ALAT abnormal, blood bilirubin increased, blood glucose increased, glycosylated haemoglobin increased, weight decreased, pancreatic enzymes decreased, nausea, vomiting, constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia, steatorrhoea, sinus bradycardia, dizziness, headache, lethargy, alopecia, hypotrichosis, hypoglycaemia, decreased appetite, hyperglycaemia, diabetes mellitus, asthenia, fatigue, injection site reactions (pain, mass, induration, nodule, pruritus), biliary dilatation, musculoskeletal pain, myalgia. Post-marketing: Pancreatic exocrine insufficiency, pancreatitis, allergic reactions (including angioedema, anaphylaxis, hypersensitivity), injection site abscess, cholecystitis and cholangitis. Prescribers should consult the Summary of Product Characteristics in relation to other side effects. Pharmaceutical precautions: Store in a refrigerator between 2^o and 8^oC in the original package.  Legal category: POM. Basic NHS cost: 60mg £551; 90mg £736; 120mg £937. Package quantity: Each box contains one 0.5ml pre-filled syringe with automatic safety system and needle. Marketing authorisation numbers: 60mg PL 34926/0005, 90mg PL 34926/0006 and 120mg PL 34926/0007. Marketing authorisation holder: Ipsen Ltd, 5th Floor, The Point, 37 North Wharf Road, London, W2 1AF. Further information can be obtained from Ipsen Ltd, 5th Floor, The Point, 37 North Wharf Road, London, W2 1AF. Tel: 01753 627777. Date of preparation of PI: June 2024. LAN-UK-000375.